• Title/Summary/Keyword: Korean Oncology

Search Result 6,238, Processing Time 0.036 seconds

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome

  • Sohn, Sang Kyun;Moon, Joon Ho;Lee, In Hee;Ahn, Jae Sook;Kim, Hyeoung Joon;Chung, Joo Seop;Shin, Ho Jin;Park, Sung Woo;Lee, Won Sik;Lee, Sang Min;Kim, Hawk;Lee, Ho Sup;Kim, Yang Soo;Cho, Yoon Young;Bae, Sung Hwa;Lee, Ji Hyun;Kim, Sung Hyun;Song, Ik Chan;Kwon, Ji Hyun;Lee, Yoo Jin
    • The Korean journal of internal medicine
    • /
    • v.33 no.6
    • /
    • pp.1194-1202
    • /
    • 2018

  • Background/Aims: This study evaluated the role of hypomethylating agents (HMA) compared to best supportive care (BSC) for patients with high or very-high (H/VH) risk myelodysplastic syndrome (MDS) according to the Revised International Prognostic Scoring System. Methods: A total of 279 H/VH risk MDS patients registered in the Korean MDS Working Party database were retrospectively analyzed. Results: HMA therapy was administered to 205 patients (73.5%), including 31 patients (11.1%) who then received allogeneic hematopoietic cell transplantation (allo-HCT), while 74 patients (26.5%) received BSC or allo-HCT without HMA. The 3-year overall survival (OS) rates were $53.1%{\pm}10.7%$ for allo-HCT with HMA, $75%{\pm}21.7%$ for allo-HCT without HMA, $17.3%{\pm}3.6%$ for HMA, and $20.8%{\pm}6.9%$ for BSC groups (p < 0.001). In the multivariate analysis, only allo-HCT was related with favorable OS (hazard ratio [HR], 0.356; p = 0.002), while very poor cytogenetic risk (HR, 5.696; p = 0.042), age ${\geq}65years$ (HR, 1.578; p = 0.022), Eastern Cooperative Oncology Group performance status (ECOG PS) 2 to 4 (HR, 2.837; p < 0.001), and transformation to acute myeloid leukemia (AML) (HR, 1.901; p = 0.001) all had an adverse effect on OS. Conclusions: For the H/VH risk group, very poor cytogenetic risk, age ${\geq}65years$, ECOG PS 2 to 4, and AML transformation were poor prognostic factors. HMA showed no benefit in terms of OS when compared to BSC. Allo-HCT was the only factor predicting a favorable long-term outcome. The use of HMA therapy did not seem to have an adverse effect on the transplantation outcomes. However, the conclusion of this study should be carefully interpreted and proven by large scale research in the future.

  • https://doi.org/10.3904/kjim.2016.426 인용 KSCI

Structure of an Oncology Information System Based on a Cost-Effective Relational Database for Small Departments of Radiation Oncology

  • Jeon, Hosang;Kim, Dong Woon;Joo, Ji Hyeon;Ki, Yongkan;Kim, Wontaek;Park, Dahl;Nam, Jiho;Kim, Dong Hyeon
    • Progress in Medical Physics
    • /
    • v.31 no.4
    • /
    • pp.172-178
    • /
    • 2020

  • Purpose: Radiation oncology information systems (ROIS) have evolved toward connecting and integrating information between radiation treatment procedures. ROIS can play an important role in utilizing modern radiotherapy techniques that have high complexity and require a large amount of information. Methods: Using AccessTM software, we have developed a relational database that is highly optimized for a radiotherapeutic workflow. Results: The prescription table was chosen as the core table to which the other tables were connected, and three types of forms-charts, worklists, and calendars- were suggested. A fast and reliable channel for delivering orders and remarks according to changes in the situation was also designed. Conclusions: We expect our ROIS design to inspire those who need to develop and manage an individual ROIS suitable for their radiation oncology departments at a low cost.

  • https://doi.org/10.14316/pmp.2020.31.4.172 인용 PDF KSCI